Senti Biosciences Holdings, Inc.(SNTI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $4.3M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SNTI Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Senti Biosciences Holdings, Inc. (SNTI), a Healthcare sector company. SNTI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $4.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Senti Biosciences Holdings, Inc. reports quarterly revenue of $16.0K, net income of $-4.2M, free cash flow of $-7.5M. Top institutional holders of SNTI by reported 13-F value include NEA Management Company,, Nantahala Capital Management,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SNTI trades on the Nasdaq exchange and files with the SEC under CIK 1854270. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Senti Biosciences Holdings, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$16.0K
Net Income
Q1 2026
$-4.2M
Free Cash Flow
Q1 2026
$-7.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-99.1% YoYNet Income
+13.5% YoYOperating Income
+25.8% YoYEPS (Diluted)
-70.5% YoYTotal Assets
-57.1% YoYOp. Cash Flow
+17.1% YoY| Metric | FY 2025 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | $22.0K -99.1% | $2.6M -40.2% | $4.3M |
| Net Income | $-61.4M +13.5% | $-71.1M -22.1% | $-58.2M |
| Operating Income | $-68.8M +25.8% | $-92.7M -49.4% | $-62.1M |
| EPS (Diluted) | $-2.73 -70.5% | $-1.60 -617.9% | $-0.22 |
| Total Assets | $51.2M -57.1% | $119.5M -33.9% | $180.8M |
| Operating Cash Flow | $-43.4M +17.1% | $-52.4M -50.1% | $-34.9M |
Get alerted when SNTI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Senti Biosciences Holdings, Inc. including:
Top Institutional Holders of SNTI
NEA Management Company, LLC
$3.1M3,775,615 shNantahala Capital Management, LLC
$721.1K888,000 shVANGUARD CAPITAL MANAGEMENT LLC
$436.5K537,504 shGEODE CAPITAL MANAGEMENT, LLC
$168.1K207,043 shVANGUARD FIDUCIARY TRUST CO
$74.0K91,193 shMenlo Ventures Management, L.P.
$29.0K35,737 shBlackRock, Inc.
$20.4K25,074 shXTX Topco Ltd
$14.0K17,277 shNORTHERN TRUST CORP
$13.6K16,778 shSTATE STREET CORP
$8.1K10,010 sh
| Fund | Value | Shares |
|---|---|---|
| NEA Management Company, LLC | $3.1M | 3,775,615 |
| Nantahala Capital Management, LLC | $721.1K | 888,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $436.5K | 537,504 |
| GEODE CAPITAL MANAGEMENT, LLC | $168.1K | 207,043 |
| VANGUARD FIDUCIARY TRUST CO | $74.0K | 91,193 |
| Menlo Ventures Management, L.P. | $29.0K | 35,737 |
| BlackRock, Inc. | $20.4K | 25,074 |
| XTX Topco Ltd | $14.0K | 17,277 |
| NORTHERN TRUST CORP | $13.6K | 16,778 |
| STATE STREET CORP | $8.1K | 10,010 |
More Healthcare Companies
View all Healthcare →Put SNTI on your watchlist
Track score changes the day Senti Biosciences Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SNTI a good stock to buy?
13F Pro's AI-powered analysis of Senti Biosciences Holdings, Inc. (SNTI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SNTI are available on the SNTI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SNTI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SNTI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Senti Biosciences Holdings, Inc.'s investment landscape.